Market Cap€43m

Last Close €11.74

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

More SynBiotic content >

Investment summary

SynBiotic has extended its lead in the European hemp and cannabis sector and is continuing to build a cannabis ‘ecosystem’, encompassing cultivation, production and trade. Based on preliminary figures, SynBiotic has delivered pro forma sales of €15m for FY21, in line with management guidance. The company has now added a target of becoming profitable as of FY23. Full consolidated financial statements will be presented at the AGM, planned in Q4.

Content on SynBiotic
SynBiotic – Management update – on track
Consumer | research Update | 9 August 2022
Cannabis leaf with magnifying glass
SynBiotic – Further acquisitions
Consumer | research Update | 6 December 2021
Cannabis leaf with magnifying glass
SynBiotic – Building a cannabis platform
Consumer | research QuickView | 1 November 2021
Cannabis leaf with magnifying glass
View more
Register to receive research on SynBiotic as it is published
Share price graph
Price performance
Actual (13.2) (26.3) (46.4)
Relative* (7.5) (19.9) (32.9)
52-week high/low €40.4/€11.3
*% relative to local index
Key management
Lars Müller CEO
Alexander Guercueyan CFO